Try our Advanced Search for more refined results

Securities and Exchange Commission v. Biochemics, Inc et al

  1. February 09, 2024

    Former Pharma Exec Faces Criminal Contempt For Fake Name

    A former leader of now-defunct BioChemics Inc. who admitted to using a false name for six years while allegedly flouting an order not to work in any aspect of the securities field is facing a criminal contempt charge and possible jail time, a Massachusetts federal judge said Friday.

  2. February 07, 2020

    Ex-BioChemics CEO Tries To Slip 'Unfair' Disclosure Order

    Former BioChemics CEO John Masiz asked a Massachusetts federal court on Friday to adjust the terms of its January order compelling him to disclose his interactions with potential investors, arguing it would unconstitutionally ruin his chances of succeeding in business.

  3. December 10, 2018

    BioChemics Receiver Taps Sunstein, Nields For IP Work

    A receiver appointed to help liquidate the assets of BioChemics Inc. as the government tries to collect on a nearly $18 million securities fraud judgment has tapped two law firms, Sunstein Kann Murphy & Timbers LLP and Nields Lemack & Frame LLC, to maintain the Massachusetts company's intellectual property.

  4. October 10, 2018

    BioChemics Receiver Named To Help SEC Sniff Out $17M

    After dodging a $17 million payment to the U.S. Securities and Exchange Commission, BioChemics Inc. will have to deal with a court-appointed receiver empowered by a Massachusetts federal judge Tuesday with the ability to find, manage and control the biopharmaceutical company's assets in an effort to make good.

  5. September 11, 2018

    BioChemics Claims It Can Pay Chunk Of $17M SEC Judgment

    The U.S. Securities and Exchange Commission and a Massachusetts federal judge appeared skeptical Tuesday of BioChemics Inc.'s claims that it can show, within three weeks, an ability to pay down a "seven-figure" chunk of the $17.2 million it owes the SEC.

  6. July 23, 2018

    BioChemics Wants More Time To Come Up With SEC's $17M

    Cash-strapped cosmetics manufacturer BioChemics Inc. opposed receivership over the weekend and asked a Massachusetts federal judge for a few more days to present a better plan to come up with $17 million for misleading investors, which it has owed the U.S. Securities and Exchange Commission for more than three years.

  7. June 06, 2018

    SEC Says BioChemics Is Unable To Pay $17M Bill To Investors

    Enough is enough, counsel for the U.S. Securities and Exchange Commission told a Massachusetts federal judge Wednesday in a letter insisting three years was ample time for BioChemics Inc. to find a buyer and cough up $17 million it owes investors for lying about product testing.

  8. March 22, 2018

    Creditor Loses Bid For Nearly $4M Of BioChemics-SEC Deal

    A Florida private equity firm cannot take priority over the U.S. Securities and Exchange Commission to recover nearly $4 million it was owed by a cash-strapped company being turned over to the government to satisfy a court judgment, a federal judge in Boston ruled from the bench Thursday.

  9. November 29, 2017

    BioChemics Obtains 11th-Hour Deposit On $17M Owed To SEC

    Attorneys for BioChemics Inc. notified a Boston federal judge on Wednesday that it secured a down payment on the $17 million it owes the U.S. Securities and Exchange Commission just 15 minutes before a hearing where government attorneys were set to pounce on the company for default.

  10. August 21, 2017

    Ex-BioChemics CEO's SEC Deal Bars Him From Leading Cos.

    The former BioChemics Inc. CEO who was accused of lying to investors about the state of the company has agreed to pay the U.S. Securities and Exchange Commission $120,000 and remain off the leadership of public companies as part of a deal cleared on Friday in Massachusetts federal court.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!